Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2017

30.09.2017 | Editorial

Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

verfasst von: Jonathan Gotfried, Ron Schey

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Excerpt

Nausea is an unpleasant sensation typically experienced in the epigastrium or throat, often accompanied by the impending urge to vomit [1]. While the neural pathways involved with nausea and emesis are generally well defined, the specific pathways involved in the nausea mechanism are not fully elucidated. Within the gastrointestinal tract, mechanical obstruction, organic disorders such as peptic ulcer disease or malignancy, and neuromuscular dysfunction such as chronic intestinal pseudo-obstruction and gastroparesis may all lead to nausea. Medications, chemotherapy, and ingested noxious agents also contribute to the pathogenesis of nausea, mainly through recognition of circulating emetic agents in the blood by central chemoreceptors [2]. Nausea is an oft-cited adverse effect of medications that often prompts therapy discontinuation. …
Literatur
1.
Zurück zum Zitat Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed
3.
Zurück zum Zitat Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582.CrossRefPubMed Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582.CrossRefPubMed
5.
Zurück zum Zitat Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11:841–850.CrossRefPubMed Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11:841–850.CrossRefPubMed
6.
Zurück zum Zitat Cryer B, Drossman D, Chey W, Webster L, Habibi S, Wang M. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-017-4680-1. Cryer B, Drossman D, Chey W, Webster L, Habibi S, Wang M. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-017-4680-1.
7.
Zurück zum Zitat Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–1724 (quiz p. 1725).CrossRefPubMedPubMedCentral Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–1724 (quiz p. 1725).CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702.CrossRefPubMed Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702.CrossRefPubMed
9.
Zurück zum Zitat Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:1566.CrossRefPubMed Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:1566.CrossRefPubMed
10.
Zurück zum Zitat Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015;75:419–425.CrossRefPubMed Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015;75:419–425.CrossRefPubMed
13.
Zurück zum Zitat Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112:356–364.CrossRefPubMed Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112:356–364.CrossRefPubMed
15.
Zurück zum Zitat Sarosiek I, Bashashati M, Alvarez A, et al. Lubiprostone accelerates intestinal transit and alleviates small intestinal bacterial overgrowth in patients with chronic constipation. Am J Med Sci. 2016;352:231–238.CrossRefPubMed Sarosiek I, Bashashati M, Alvarez A, et al. Lubiprostone accelerates intestinal transit and alleviates small intestinal bacterial overgrowth in patients with chronic constipation. Am J Med Sci. 2016;352:231–238.CrossRefPubMed
17.
Zurück zum Zitat Knudsen K, Krogh K, Ostergaard K, Borghammer P. Constipation in Parkinson’s disease: subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017;32:94–105. doi:10.1002/mds.26866.CrossRefPubMed Knudsen K, Krogh K, Ostergaard K, Borghammer P. Constipation in Parkinson’s disease: subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017;32:94–105. doi:10.​1002/​mds.​26866.CrossRefPubMed
18.
Zurück zum Zitat Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–621. doi:10.1038/ajg.2016.611.CrossRefPubMed Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–621. doi:10.​1038/​ajg.​2016.​611.CrossRefPubMed
20.
Zurück zum Zitat Atluri D, Chandar A, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:499–509.CrossRefPubMed Atluri D, Chandar A, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:499–509.CrossRefPubMed
Metadaten
Titel
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders
verfasst von
Jonathan Gotfried
Ron Schey
Publikationsdatum
30.09.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4773-x

Weitere Artikel der Ausgabe 12/2017

Digestive Diseases and Sciences 12/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.